On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.

Take two at bedtime.

If preliminary results were correct, simufilam could be the long-sought-after cure for dementia, the Holy Grail of ...

A class action lawsuit was filed against Cassava Sciences Inc. (SAVA) by Levi & Korsinsky on December 12, 2024. The ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Cassava's leading drug candidate, simufilam. Defendants' statements included, among other ...

Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...

CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against ...

CONTACT US HERE: ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning Cassava’s leading drug candidate, simufilam. Defendants’ statements ...

The survey found that more than half of those homeowners said they expect bad news when they renew and they anticipate their monthly payment will increase. Make your Valentine’s Day extra ...

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during ...